Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism

Sorafenib is one of the options for advanced hepatocellular carcinoma treatment and has been shown to extend median overall survival. However, sorafenib resistance often develops a few months after treatment. Hence, developing various strategies to overcome sorafenib resistance and understand the po...

Descripción completa

Detalles Bibliográficos
Autores principales: Shueng, Pei-Wei, Chan, Hui-Wen, Lin, Wei-Chan, Kuo, Deng-Yu, Chuang, Hui-Yen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223797/
https://www.ncbi.nlm.nih.gov/pubmed/35742944
http://dx.doi.org/10.3390/ijms23126501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223797/
https://www.ncbi.nlm.nih.gov/pubmed/35742944
http://dx.doi.org/10.3390/ijms23126501

Ejemplares similares